NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $79.00 -2.07 (-2.55%) Closing price 04:00 PM EasternExtended Trading$78.94 -0.06 (-0.08%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TransMedics Group Stock (NASDAQ:TMDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransMedics Group alerts:Sign Up Key Stats Today's Range$77.50▼$80.2850-Day Range$76.49▼$94.7752-Week Range$60.10▼$156.00Volume949,379 shsAverage Volume783,153 shsMarket Capitalization$2.73 billionP/E Ratio20.31Dividend YieldN/APrice Target$121.00Consensus RatingHold Company Overview TransMedics Group, Inc. is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant. The company offers OCS solutions for heart, lung and liver transplantation. In addition to its medical devices, TransMedics provides related services, including organ procurement, preservation, transportation and transplant support through its National OCS Program. These services are intended to help transplant centers manage the logistics of retrieving and delivering donor organs. Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets. The company was founded by Waleed H. Hassanein, who serves as its president and chief executive officer. TransMedics became a publicly traded company on the Nasdaq under the symbol TMDX in 2019.AI Generated. May Contain Errors. Read More TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 88% of companies evaluated by MarketBeat, and ranked 29th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingTransMedics Group has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialTransMedics Group has a consensus price target of $121.00, representing about 53.2% upside from its current price of $79.00.Amount of Analyst CoverageTransMedics Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth54.79% Earnings GrowthEarnings for TransMedics Group are expected to grow by 54.79% in the coming year, from $1.46 to $2.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 41.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.83.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 41.15, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.15.Price to Earnings Growth RatioTransMedics Group has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 5.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.79% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 10.68, which indicates bearish sentiment.Change versus previous monthShort interest in TransMedics Group has recently decreased by 1.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.52 News SentimentTransMedics Group has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for TransMedics Group this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows7 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $109,058.00 in company stock, which represents 0.0040% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,058.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders6.90% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TMDX Stock News HeadlinesBarclays initiates coverage of TransMedics Group at overweight4 hours ago | msn.comTransMedics Group consensus price target rises 10.91% to MX$1,984.964 hours ago | msn.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 8 at 1:00 AM | Banyan Hill Publishing (Ad)TransMedics Group, Inc. (NASDAQ:TMDX) Stock Rated "Hold" by Sell-Side AnalystsOctober 5 at 2:28 AM | americanbankingnews.comTransMedics Group (TMDX) Stock Looks Below Fair Value On EarningsOctober 4, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)October 3, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)October 3, 2026 | theglobeandmail.comInsider Buying: TransMedics Group (NASDAQ:TMDX) Director Purchases $109,057.68 in StockSeptember 15, 2026 | insidertrades.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $121.65 at the beginning of the year. Since then, TMDX stock has decreased by 35.1% and is now trading at $79.00. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by $0.06. The business's revenue was up 20.7% on a year-over-year basis. Read the conference call transcript. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $91 million in an IPO on Thursday, May 2nd 2019. The company issued 5,690,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's top institutional shareholders include Zevenbergen Capital Investments LLC (0.77%), Congress Asset Management Co. (0.73%), Central Pacific Bank Trust Division (0.02%) and Plan A Wealth LLC (0.02%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Nicholas Corcoran, Miriam Provost, Stephen Gordon, Tamer I Khayal, Thomas J Gunderson, David Weill, Gerardo Hernandez, Anil P Ranganath, Stephanie Lovell and Edward M Basile. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings8/04/2026Today10/08/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TMDX's financial health is in the Green zone, according to TradeSmith. TMDX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees898Year Founded1998Price Target and Rating Average Price Target for TransMedics Group$121.00 High Price Target$175.00 Low Price Target$77.00 Potential Upside/Downside+53.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$3.89 Trailing P/E Ratio20.31 Forward P/E Ratio54.11 P/E Growth1.11Net Income$190.29 million Net Margins22.69% Pretax Margin10.85% Return on Equity15.88% Return on Assets5.95% Debt Debt-to-Equity Ratio1.62 Current Ratio6.62 Quick Ratio6.07 Sales & Book Value Annual Sales$605.49 million Price / Sales4.51 Cash Flow$3.83 per share Price / Cash Flow20.64 Book Value$13.79 per share Price / Book5.73Miscellaneous Outstanding Shares34,560,000Free Float32,176,000Market Cap$2.73 billion OptionableOptionable Beta1.94 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TMDX) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
